Drug-induced weight gain: Rethinking our choices

Journal of Family Practice

Volumn 65, Issue 11, 2016, Pages 780-788

  Saunders, Katherine H ^a   Igel, Leon I ^a   Shukla, Alpana P ^a   Aronne, Louis J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; FLUOXETINE; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NALTREXONE; PAROXETINE; PIOGLITAZONE; PRAMLINTIDE; SERTRALINE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; PRESCRIPTION DRUG;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY WEIGHT; DEPRESSION; DIABETES MELLITUS; DIABETIC PATIENT; DRUG CHOICE; DRUG INDUCED DISEASE; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; MEDICINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; RISK ASSESSMENT; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; ADULT; ADVERSE DRUG REACTION; BODY WEIGHT GAIN; CASE REPORT; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OVERWEIGHT; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTION DRUGS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84999016852     PISSN: 00943509     EISSN: 15337294     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Serretti A, Mandelli L. Antidepressants and body weight: A comprehensive review and meta-analysis. J Clin Psychiatry. 2010; 71: 1259-1272.
2. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100: 342-362.
3. Apovian CM, Aronne L, Powell AG. Clinical Management of Obesity. West Islip, NY: Professional Communications, Inc., 2015.
4. Aronne LJ. A Practical Guide to Drug-induced Weight Gain. Minneapolis, Minn: McGraw-Hill; 2002.
5. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: A systematic review. QJM. 2007; 100: 395-404.
6. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2016 executive summary. Endocr Pract. 2016; 22: 84-113.
7. Aronne LJ. Drug-induced weight gain: Non-CNS medications. In: A Practical Guide to Drug-Induced Weight Gain. Minneapolis, Minn: McGraw-Hill: 2002: 77-91.
8. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2015; 100: 363-370.
9. Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010; 303: 1410-1418.
10. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-2443.
11. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373: 473-481.
12. Malin SK, Kashyap SR. Effects of metformin on weight loss: Potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014; 21: 323-329.
13. Igel LI, Sinha A, Saunders KH, et al. Metformin: An old therapy that deserves a new indication for the treatment of obesity. Curr Atheroscler Rep. 2016; 18: 16.
14. US Food and Drug Administration. FDA approves weight-management drug Saxenda. December 23, 2014. Available at: Http: // www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm427913.htm. Accessed October 1, 2016.
15. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat Rev Endocrinol. 2012; 8: 495-502.
16. van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005; 28: 154-163.
17. Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab. 2012; 14: 795-802.
18. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: A proof-of-concept study. Diabetes Care. 2010; 33: 1509-1515.
19. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials. Diabetes Metab. 2012; 38: 89-101.
20. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 2003; 26: 784-790.
21. Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: A phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007; 92: 2977-2983.
22. Saunders KH, Kumar RB, Igel LI, et al. Pharmacologic approaches to weight management: Recent gains and shortfalls in combating obesity. Curr Atheroscler Rep. 2016; 18: 36.
23. Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: Pathogenesis, cardiovascular risk, and treatment-A position paper of the Obesity Society and the American Society of Hypertension. Obesity (Silver Spring). 2013; 21: 8-24.
24. Messerli FH, Bell DS, Fonseca V, et al. Body weight changes with beta-blocker use: Results from GEMINI. Am J Med. 2007; 120: 610-615.
25. Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: Potential role of weight gain. Obes Rev. 2001; 2: 275-280.
26. Sharma AM, Pischon T, Hardt S, et al. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension. 2001; 37: 250-254.
27. Manrique C, Whaley-Connell A, Sowers JR. Nebivolol in obese and non-obese hypertensive patients. J Clin Hypertens (Greenwich). 2009; 11: 309-315.
28. Norris SL, Zhang X, Avenell A, et al. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005; (1): CD004096.
29. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al. Differentiating antidepressants of the future: Efficacy and safety. Pharmacol Ther. 2007; 113: 134-153.
30. Gadde KM, Xiong GL. Bupropion for weight reduction. Expert Rev Neurother. 2007; 7: 17-24.
31. Arterburn D, Sofer T, Boudreau DM, et al. Long-term weight change after initiating second-generation antidepressants. J Clin Med. 2016; 5: PiiE48.
32. US Food and Drug Administration. FDA approves weight-management drug Contrave. September 10, 2014. Available at: Http: // www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm413896.htm. Accessed October 1, 2016.